Sanford J. Madigan, Ph.D., President and Chief Operating Officer

Dr. Madigan has over 16 years of industry experience and has been instrumental in developing companies' infrastructure, establishing strategic direction, licensing founding and value-added technologies, negotiating strategic partnerships and corporate acquisitions.

Dr. Madigan most recently served as a co-founder and Chief Executive Officer of Strategic Enzyme Applications (SEA), a San Diego-based clean technology company that was established, in part, as a strategic relationship with Monsanto. Prior to founding SEA, Dr. Madigan served in various venture-backed biotechnology companies; participating as a founder and/or senior manager in BioVerdant, Nereus Pharmaceuticals, Ambit, Xenopharm (acquired by Deltagen), X-Ceptor (acquired by Exelixis) and SIBIA Neurosciences (acquired by Merck).

Dr. Madigan received his B.S. in Biochemistry and a Ph.D. in Genetics from The State University of New York at Stony Brook where, as a graduate student, he was awarded the Abrahams Memorial Award for outstanding potential for basic research. He performed his post-doctoral training at The Salk Institute for Biological Studies in La Jolla, California.

Sergio Duron, Ph.D., Vice President, Chemistry and Drug Discovery

Dr. Duron leads preclinical development for Sova. Prior to Sova, Dr. Duron served as Director of Chemistry at Zacharon Pharmaceuticals (acquired by BioMarin) and Vice President of Chemistry at Afraxis (acquired by Genentech), both Avalon Ventures portfolio companies. Prior to Afraxis, Dr. Duron was responsible for identifying two IND candidates at Kalypsys, one approved to enter Phase II. Dr. Duron is experienced in drug discovery and preclinical development in areas of pain, inflammation, metabolic diseases and oncology.

Dr. Duron served as a post-doctoral fellow at The Scripps Research Institute after receiving his Ph.D. in organic chemistry from the University of Illinois at Urbana-Champaign.